A PET Study of ENX-104 in Healthy Volunteers
NCT07253272 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2025-11-28
Summary
The study is designed to evaluate the D2/D3 receptor occupancy (RO), safety, tolerability, and pharmacokinetics (PK) of ENX-104 in healthy volunteers.
Conditions
- Healthy Volunteers
Interventions
- DRUG
-
ENX-104
Oral solution
Sponsors & Collaborators
-
Engrail Therapeutics INC
lead INDUSTRY
Principal Investigators
-
David George Steel, MBChB · Parexel
Study Design
- Allocation
- NA
- Purpose
- OTHER
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 23 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-02-24
- Primary Completion
- 2025-09-02
- Completion
- 2025-09-02
Countries
- United Kingdom
Study Locations
More Related Trials
-
PD-L1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer
NCT04564482 ·Status: RECRUITING ·Phase: NA
-
Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or Inflammation
NCT01103310 ·Status: COMPLETED ·Phase: PHASE1
-
PET Study of Repeated ASN51 in Healthy Volunteers
NCT05725005 ·Status: COMPLETED ·Phase: PHASE1
-
68Ga-labeled NY104 PET Imaging in Patients
NCT05638256 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Application of the CD73-Targeted Probe ⁶⁸Ga-DOTA-mPNE PET/CT Imaging in the Diagnosis of Malignant Tumors
NCT07023640 ·Status: RECRUITING ·Phase: NA
-
PET-CT Based Radiotherapy in Esophageal Cancer Patients
NCT01156831 ·Status: COMPLETED
-
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
NCT06337084 ·Status: RECRUITING ·Phase: PHASE1
-
A Small-molecule Carbonic Anhydrase IX Targeting PET Tracer in Clear Cell Renal Cell Carcinoma
NCT05728515 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Study of [11C]JNJ-42491293, a Possible PET Ligand for the mGlu2 Receptor, in Healthy Adult Volunteers
NCT01359852 ·Status: COMPLETED ·Phase: PHASE1
-
Pembrolizumab-PET Imaging
NCT02760225 ·Status: COMPLETED ·Phase: NA
-
Clinical Study of 18F-LNC1007 Injection PET/CT
NCT06471712 ·Status: COMPLETED ·Phase: PHASE1
-
MPDL3280A-imaging-IST-UMCG
NCT02453984 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
PennPET Explorer Scanner Evaluation
NCT04617912 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer
NCT01186601 ·Status: COMPLETED ·Phase: PHASE1
-
AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm
NCT03453489 ·Status: COMPLETED ·Phase: PHASE2
-
Long COVID-19 [11C]CPPC Study
NCT06223971 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Radiation Dosimetry, Metabolism, Safety, Tolerability and Positron Emission Tomography/Computed Tomography (PET/CT) Imaging With BAY 85-8050 in Healthy Volunteers and Patients
NCT00961831 ·Status: COMPLETED ·Phase: PHASE1
-
68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients
NCT01527058 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Basmisanil Positron Emission Tomography Study in Japanese Volunteers
NCT02534207 ·Status: COMPLETED ·Phase: PHASE1
-
EXPLORER PET/CT in Healthy Volunteers
NCT04110743 ·Status: COMPLETED ·Phase: NA
-
ONO-2952 Single-dose PET Study in Healthy Adult Subjects
NCT01613703 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors
NCT02810600 ·Status: COMPLETED
-
PET Imaging Study to Evaluate the mGlu5r Occupancy Following ADX48621 (Dipraglurant) Administration
NCT02447640 ·Status: COMPLETED ·Phase: PHASE1
-
Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases
NCT06690736 ·Status: RECRUITING ·Phase: NA
-
Nectin-4 Targeting ADC Probe for PET Imaging in Solid Tumors
NCT05322512 ·Status: NOT_YET_RECRUITING ·Phase: NA